CBD modulates immune function through multiple mechanisms—suppressing inflammation, regulating T cells, and inducing macrophage death—with therapeutic potential for autoimmune diseases, though most evidence is preclinical.
Immunology researchers, people with autoimmune conditions interested in CBD, and pharmaceutical scientists working on CBD delivery systems.
What the researchers found
This comprehensive review maps how CBD interacts with the immune system, and the picture is remarkably broad. CBD doesn't have a single immune effect—it operates through multiple simultaneous mechanisms:
It regulates T cell activity, the immune cells that drive autoimmune attacks. It induces apoptosis (programmed death) in macrophages, the immune cells that fuel chronic inflammation. It suppresses pro-inflammatory cytokines—the chemical messengers that amplify inflammatory responses. And it modulates signaling pathways involved in immune homeostasis.
Preclinical and clinical studies have shown these effects translate into potential therapies for autoimmune diseases: Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. CBD has also shown promise for neuropathic pain and cancer therapy through immune-related mechanisms.
The review also covers a frontier of CBD research: nanotechnology-based delivery systems. These engineered nanoparticles improve CBD's solubility and bioavailability (addressing the same problem as RTHC-00179's DehydraTECH approach) and can target specific tissues, potentially enhancing therapeutic effects while reducing doses.
The challenge: most of this evidence is preclinical. The gap between showing immune modulation in a lab dish or mouse model and proving clinical benefit in human disease is substantial.
Why it matters
Autoimmune diseases affect roughly 5–8% of the population and current treatments (immunosuppressants, biologics) carry significant side effects. If CBD can modulate immune function more selectively—suppressing harmful autoimmune responses while preserving necessary immunity—it could fill an important therapeutic gap. The nanotechnology delivery advances could address CBD's poor bioavailability, which has limited its clinical efficacy to date.
The numbers in context
CBD modulates: T cell activity, macrophage apoptosis, pro-inflammatory cytokine production, and multiple inflammatory signaling pathways. Potential applications: Type 1 diabetes, MS, rheumatoid arthritis, IBD, neuropathic pain, cancer.
How the study worked
Comprehensive literature review searching PubMed, Scopus, and Web of Science for preclinical and clinical studies on CBD's immunomodulatory effects. Covers mechanisms of action, disease-specific applications, and nanotechnology delivery advances.
Who was studied
Comprehensive review of preclinical and clinical studies on CBD's immunomodulatory effects.
What this study cannot tell us
Much of the evidence is preclinical (cell cultures and animal models). Doses used in preclinical studies often don't translate to achievable human doses. The review covers a very broad range of conditions, which limits depth on any single disease. Publication bias may favor positive results. Clinical trial evidence for CBD in autoimmune diseases specifically is still sparse.
How to read the evidence
Comprehensive narrative review synthesizing preclinical and clinical evidence—broad in scope but limited by the predominantly preclinical evidence base.
When this study was published
Published in 2025, incorporating the latest nanotechnology delivery research.
The bigger picture
This immunological perspective connects to RTHC-00182's null result for CBD in osteoarthritis (which has both inflammatory and mechanical components) and RTHC-00158's pain-specific benefit from THC:CBD in cancer. Understanding which immune mechanisms CBD actually engages in vivo could explain why it works for some conditions and not others. The nanotechnology delivery section also connects to RTHC-00179's DehydraTECH formulation—both addressing the fundamental bioavailability problem from different technological angles.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Which autoimmune conditions are closest to having clinical trial support for CBD? Do CBD's immunomodulatory effects persist with chronic use, or does tolerance develop? Could CBD's immune-suppressing properties be harmful in immunocompromised patients?
Read the original research
Cannabidiol as an immune modulator: A comprehensive review.
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 33(3), 11
The Saudi Pharmaceutical Journal is a peer-reviewed journal focusing on pharmaceutical sciences and research.
Citation
Mujahid, Khizra; Rasheed, Muhammad Shahzaib; Sabir, Azka; Nam, Jutaek; Ramzan, Talha; Ashraf, Waseem; Imran, Imran. (2025). Cannabidiol as an immune modulator: A comprehensive review.. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 33(3), 11. https://doi.org/10.1007/s44446-025-00005-7
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk